Motus GI (MOTS) Given Daily Media Impact Score of 0.18
Media coverage about Motus GI (NASDAQ:MOTS) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Motus GI earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the company an impact score of 48.6109500494805 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts recently weighed in on MOTS shares. ValuEngine upgraded shares of Motus GI from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. EuroPacific Canada started coverage on shares of Motus GI in a research report on Thursday, May 31st. They set a “buy” rating and a $12.00 price objective for the company. Oppenheimer set a $10.00 price objective on shares of Motus GI and gave the stock a “buy” rating in a research report on Friday, July 13th. Finally, Zacks Investment Research cut shares of Motus GI from a “hold” rating to a “sell” rating in a research report on Wednesday, July 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $9.67.
Motus GI traded up $0.24, reaching $5.99, during midday trading on Friday, Marketbeat.com reports. 18,911 shares of the company were exchanged, compared to its average volume of 51,908. Motus GI has a one year low of $3.75 and a one year high of $10.66. The stock has a market cap of $89.96 million and a price-to-earnings ratio of -4.68.
In related news, Director Gary E. Jacobs acquired 5,000 shares of Motus GI stock in a transaction on Friday, May 18th. The stock was purchased at an average cost of $5.24 per share, with a total value of $26,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
See Also: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.